Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.37 |
| ▸ | SGK1 | O00141 | 2/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528846 | 0.86 | RAB9A (0.40) | NPY5RKITMAPK14AOC3SGK1 | |
| SCHEMBL90838 | 0.84 | ULK1 (0.40) | KMT2AMAPK14ULK1 | |
| SCHEMBL91041 | 0.84 | SCN9A (0.33) | NPY5RKITMAPK14AOC3ULK1 | |
| SCHEMBL90944 | 0.84 | USP30 (0.44) | NPY5RAOC3ULK1 | |
| SCHEMBL91038 | 0.74 | GRIA2 (0.47) | KITAOC3MAP2K7MAP2K4 | |
| SCHEMBL90946 | 0.72 | KMT2A (0.41) | KMT2A | |
| SCHEMBL91023 | 0.72 | MKNK1 (0.57) | KMT2AMAP2K7MAP2K4 | |
| SCHEMBL91042 | 0.71 | ULK1 (0.43) | ULK1 | |
| SCHEMBL8547726 | 0.70 | MKNK1 (0.39) | KMT2ASGK1 | |
| SCHEMBL91004 | 0.70 | DRD4 (0.57) | KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | CPT1A 3953/4885KMT2A 2284/4885TDP1 4001/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | CPT1A 3953/4885KMT2A 2284/4885TDP1 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.